출판: MarketsandMarkets（마켓츠앤드마켓츠）출판년월：2021년11월
・제품(혈당 모니터링, COVID, HIV, STD, HAI, 인플루엔자, 열대병 및 호흡기 질환), 기술(신속 검사, 분자 진단), 사용자(병원, 가정 의료) – 2026년까지 예측
ASEAN and North Asian Point of Care/Rapid Diagnostics Market by Product (Glucose Monitoring, COVID, HIV, STDs, HAIs, Influenza, Tropical & Respiratory diseases), Technique (Rapid test, Molecular diagnostics), User (Hospital, Home Care) – Forecast to 2026
| 폐이지수 | 224 |
| 도표수 | 50 |
| 구성 | 영문조사보고서 |
–
| 목차 | 견적문의의뢰 |
–
The ASEAN and North Asian Point of Care/Rapid Diagnostics market size is expected to grow from an estimated USD 2.0 billion in 2021 to USD 3.9 billion by 2026, at a CAGR of 13.0%. The growing demand for accurate and early diagnostic methodologies, modernization and expansion of healthcare infrastructure and significant disease prevalence are the major factors that are expected to drive the growth of the ASEAN and North Asian Point of Care/Rapid Diagnostics market during the forecast period.
아세안 및 북아시아 현장 진료/신속 진단 시장 규모는 CAGR 13.0%로 2021년 20억 달러에서 2026년 39억 달러로 성장할 것으로 예상됩니다. 정확하고 조기 진단 방법론에 대한 수요 증가, 의료 인프라의 현대화 및 확장, 상당한 질병 유병률은 예측 기간 동안 ASEAN 및 북아시아 현장 진료/신속 진단 시장의 성장을 이끌 것으로 예상되는 주요 요인입니다.
“Infectious Disease Diagnostics are the largest product segment in the ASEAN and North Asian Point of Care/Rapid Diagnostics market”
Based on product, the ASEAN and North Asian Point of Care/Rapid Diagnostics market is segmented into Infectious Disease Diagnostics, Glucose Monitoring, Cancer Marker Testing, Cardiometabolic Monitoring, Cholesterol Testing, Coagulation Monitoring, Hematology Testing, Urinalysis, Drugs-of-abuse Testing, Pregnancy & Fertility Testing, Fecal Occult Testing and other PoC Diagnostic products. Infectious diseases are expected to account for the largest share of the ASEAN and North Asian Point of Care/Rapid Diagnostics market in 2021. Infectious disease diagnostics dominate the ASEAN and North Asian Point of Care/Rapid Diagnostics market owing to greater patient population and extensive market availability.
“Molecular Diagnostics is estimated to be having the highest demand in the technology segment in the ASEAN and North Asian Point of Care/Rapid Diagnostics market”
On the basis of technology, the ASEAN and North Asian Point of Care/Rapid Diagnostics market is segmented into Lateral Flow Assays, Immunoassays, Molecular Diagnostics, Microfluidics, Rapid Testing and Dipsticks. Molecular diagnostic technologies are projected to experience higher demand owing to supportive regulations, techno-commercial advantages, and rising public awareness.
“South Korea, Hong Kong, and Taiwan are among the top ASEAN countries to dominate the point of care diagnostics market.”
The ASEAN and North Asian Point of Care/Rapid Diagnostics market is segmented into South Korea, Hong Kong, Indonesia, Thailand, Philippines, Vietnam, Malaysia, Singapore, Taiwan, Myanmar, Laos and Cambodia. During the forecast period of 2021 to 2026, South Korea, Hong Kong and Taiwan will dominate the point of care diagnostics market. The high growth in this regional market is majorly attributed to factors such as the growing demand for accurate and early diagnostic methodologies.
Breakdown of Primaries:
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
• By Company Type: Tier 1–55%; Tier 2–20%; and Tier 3–25%
• By Designation: C Level–40%; Directors–35%; and Others–25%
• By Country: South Korea–14%; Singapore–11%; Malaysia–11%; Indonesia–10%; Taiwan–10%; and Others–44%
The major players operating in the ASEAN and North Asian Point of Care/Rapid Diagnostics market are Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Abbott Laboratories (US), Danaher Corporation (US), Becton, Dickinson and Company (US), Sysmex (Japan), Cardinal Health (US), Quidel (US), GE Healthcare (US) EKF Diagnostics (UK), bioMérieux SA (France), Accubiotech (China), PTS Diagnostics (US), Chembio Diagnostics (US) Trinity Biotech (Ireland), Johnson and Johnson(US), Sekisui Diagnostics (US), Nova Biomedical (US), Thermo Fisher Scientific (US), Ortho Clinical Diagnostics (US) and Bio-Techne (US).
Product launches & approvals, mainly owing to the COVID-19 pandemic were the key strategies adopted by market players to achieve growth in the market.
Research Coverage:
This report studies the ASEAN and North Asian Point of Care/Rapid Diagnostics market based on product, technology, end user and country. The major market drivers and restraints are also covered in this report. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends, prospects, and contributions to the total market, and forecasts the revenue of the market segments with respect to four main regions.
Why Buy this Report?
1. The report identifies and addresses the key markets for the ASEAN and North Asian Point of Care/Rapid Diagnostics market, which would help equipment manufacturers and service providers review the growth in demand.
2. The report helps system providers understand the pulse of the market and provides insights into drivers, restraints, opportunities, and challenges.
3. The report will help key players understand the strategies of their competitors better and help them in making better strategic decisions.
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.2.2 GEOGRAPHIC SCOPE
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY USED FOR THE STUDY
1.4 KEY STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.3 MARKET DATA VALIDATION AND TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
FIGURE1: ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
FIGURE2: ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER
4 MARKET OVERVIEW
4.1 ASIA: MARKET DYNAMICS
4.1.1 MAJOR DRIVERS
4.1.2 KEY RESTRAINTS
4.1.3 KEY GROWTH OPPORTUNITIES
4.1.4 INDUSTRY-SPECIFIC CHALLENGES
4.2 ASIA: PRICING TREND ANALYSIS FOR TARGET PRODUCT SEGMENTS (IN TERMS OF USD, AS OF 2020/21)
4.2.1 ASEAN
4.2.2 SOUTH KOREA
4.2.3 GREATER CHINA
4.2.4 OTHER ASIAN COUNTRIES
4.3 ASIA: COVID-SPECIFIC INDUSTRY TRENDS
4.4 ASIA: REGULATORY LANDSCAPE (AS OF 2020/21)
5 POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY PRODUCT TYPE (USD MILLION; 2019 — 2026)*
TABLE 1 ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 2 ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
5.1 INFECTIOUS DISEASE DIAGNOSTICS
5.1.1 COVID TESTING
5.1.2 HIV TESTING
5.1.3 RESPIRATORY INFECTION TESTING
5.1.4 INFLUENZA TESTING
5.1.5 TROPICAL DISEASE TESTING
5.1.6 STD TESTING
5.1.7 HEPATITIS C TESTING
5.1.8 HOSPITAL ACQUIRED INFECTION TESTING
5.1.9 OTHER INFECTIOUS DISEASE TESTING
5.2 GLUCOSE MONITORING
5.2.1 GLUCOSE TEST STRIPS
5.2.2 GLUCOMETERS
5.2.3 LANCETS
5.3 CARDIOMETABOLIC MONITORING
5.3.1 CARDIAC MARKER TESTING
5.3.2 HBA1C TESTING
5.3.3 BLOOD GAS AND ELECTROLYTE TESTING
5.4 COAGULATION MONITORING
5.5 PREGNANCY AND FERTILITY TESTING
5.6 URINALYSIS
5.7 CANCER MARKER TESTING
5.8 CHOLESTEROL TESTING
5.9 HEMATOLOGY TESTING
5.10 FECAL OCCULT TESTING
5.11 DRUG OF ABUSE TESTING
5.12 OTHER POC PRODUCTS
6 POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY TECHNOLOGY (USD MILLION; 2019 — 2026)*
TABLE 3 ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
6.1 RAPID TESTS
6.2 IMMUNOASSAY
6.3 LATERAL FLOW ASSAY
6.4 MICROFLUIDICS
6.5 MOLECULAR DIAGNOSTICS
6.6 DIPSTICKS
7 POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY END USER (USD MILLION; 2019 — 2026)*
TABLE 4 ASEAN AND NORTH ASIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
7.1 HOSPITALS AND CRITICAL CARE CENTERS
7.2 OUTPATIENT AND AMBULATORY CARE CENTERS
7.3 HOME CARE
7.4 OTHER END USERS
8 POINT OF CARE DIAGNOSTICS MARKET VALUE DATA, BY COUNTRY (USD MILLION; 2019 — 2026)*
8.1 INDONESIA
TABLE 5 INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 6 INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 7 INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 8 INDONESIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.2 LAOS AND CAMBODIA
TABLE 9 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 10 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 11 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 12 LAOS AND CAMBODIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.3 MALAYSIA
TABLE 13 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 14 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 15 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 16 MALAYSIA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.4 MYANMAR
TABLE 17 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 18 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 19 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 20 MYANMAR POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.5 PHILIPPINES
TABLE 21 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 22 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 23 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 24 PHILIPPINES POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.6 SINGAPORE
TABLE 25 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 26 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 27 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 28 SINGAPORE POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.7 THAILAND
TABLE 29 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 30 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 31 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 32 THAILAND POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.8 VIETNAM
TABLE 33 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 34 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 35 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 36 VIETNAM POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.9 SOUTH KOREA
TABLE 37 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 38 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 39 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 40 SOUTH KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.10 HONG KONG
TABLE 41 HONG KONG KOREA POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 42 HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 43 HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 44 HONG KONG POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
8.11 TAIWAN
TABLE 45 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
TABLE 46 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY TYPE, 2019-2026 (USD MILLION)
TABLE 47 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2026 (USD MILLION)
TABLE 48 TAIWAN POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2019-2026 (USD MILLION)
9 COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 ASEAN: POINT OF CARE DIAGNOSTICS MARKET SHARE ANALYSIS BY TOP 5 VENDORS (IN TERMS OF %REVENUE, IN 2020)
9.3 ASEAN: COMPETITIVE SCENARIO (2018-2021)
9.3.1 PRODUCT LAUNCHES
9.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
9.3.3 GEOGRAPHIC EXPANSIONS
9.3.4 ACQUISTIONS
9.4 ASEAN: COMPETITIVE LEADERSHIP MAPPING FOR MAJOR PLAYERS (AS OF 2021)
9.4.1 PARTICIPANTS
9.4.2 EMERGING LEADERS
9.4.3 PERVASIVE PLAYERS
9.4.4 STARS
10 COMPANY PROFILES**
(Business overview, product portfolio, industry-specific developments in 2018-2021***)
10.1 ABBOTT LABORATORIES
10.2 ACCUBIOTECH
10.3 BECTON. DICKINSON AND COMPANY
10.4 JOHNSON & JOHNSON
10.5 BIOMERIEUX
10.6 GE HEALTHCARE
10.7 ORTHOCLINICAL DIAGNOSTICS
10.8 BIOTECHNE
10.9 EKF DIAGNOSTICS
10.10 SYSMEX
10.11 ROCHE DIAGNOSTICS
10.12 SEKISUI DIAGNOSTICS
10.13 SIEMENS HEALTHINEERS
10.14 THERMO FISHER SCIENTIFIC
10.15 TRINITY BIOTECH
10.16 CHEMBIO
10. 17 CARDINAL HEALTH
10. 18 PTS DIAGNOSTICS
10.19 QUIDEL
10.20 INSTRUMENTATION LABORATORY (A WERFEN COMPAN
11 APPENDIX
お問合せフォーム
